Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, ,Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
- Revenue in NZD (TTM)195.41m
- Net income in NZD15.61m
- Incorporated1997
- Employees110.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma Ltd | 161.43m | 12.79m | 256.40m | 831.00 | 20.30 | 1.26 | 12.76 | 1.59 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Elutia Inc | 42.53m | -119.30m | 257.65m | 54.00 | -- | -- | -- | 6.06 | -3.05 | -2.86 | 1.12 | -2.28 | 0.5303 | 2.32 | 5.08 | 462,722.20 | -148.77 | -42.93 | -1,212.93 | -79.34 | 42.46 | 43.32 | -280.53 | -64.16 | 0.6842 | -0.6561 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Hyloris Pharmaceuticals SA | 9.12m | -21.95m | 260.29m | 24.00 | -- | 4.18 | -- | 28.55 | -0.4281 | -0.4281 | 0.1789 | 1.24 | 0.0989 | -- | 1.19 | -- | -23.82 | -22.79 | -28.07 | -28.09 | 96.95 | 92.05 | -240.77 | -815.53 | -- | -- | 0.0516 | -- | 131.89 | 87.11 | -29.18 | -- | 89.12 | -- |
| Hangzhou Tianmushan Phrmtcl ntrprs C Ltd | 37.66m | -3.41m | 260.58m | 380.00 | -- | 33.17 | -- | 6.92 | -0.1192 | -0.1192 | 1.32 | 0.2746 | 0.4537 | 2.29 | 3.43 | 421,978.40 | -4.39 | -6.93 | -22.04 | -18.92 | 36.69 | 33.95 | -9.69 | -16.42 | 0.4497 | -1.95 | 0.6938 | -- | 11.82 | -19.42 | 43.35 | -- | -24.89 | -- |
| AFT Pharmaceuticals Ltd | 195.41m | 15.61m | 266.36m | 110.00 | 17.06 | 3.03 | 15.12 | 1.36 | 0.1489 | 0.1489 | 1.86 | 0.8372 | 1.25 | 2.34 | 4.30 | 1,776,464.00 | 9.96 | 11.44 | 13.72 | 16.49 | 45.17 | 45.65 | 7.99 | 9.50 | 1.23 | 6.69 | 0.2683 | 4.43 | 24.75 | 18.08 | 46.51 | -- | 22.42 | -- |
| Fuso Pharmaceutical Industries Ltd | 632.04m | 24.03m | 270.41m | 1.31k | 10.15 | 0.589 | 5.51 | 0.4278 | 257.39 | 257.39 | 6,774.96 | 4,436.49 | 0.7581 | 3.07 | 2.33 | 44,163,730.00 | 2.89 | 1.91 | 4.97 | 3.09 | 26.58 | 26.92 | 3.81 | 2.69 | 0.9406 | 50.75 | 0.267 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
| LifeVantage Corp | 333.61m | 7.04m | 275.64m | 217.00 | 40.51 | 5.83 | 21.33 | 0.8262 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 06 Nov 2024 | 7.52m | 7.17% |
| Guardians of New Zealand Superannuationas of 30 Apr 2024 | 1.70m | 1.62% |
| Salt Funds Management Ltd.as of 30 Apr 2024 | 319.83k | 0.31% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 73.45k | 0.07% |
| FCA Corp.as of 30 Sep 2024 | 46.00k | 0.04% |
